查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1989030

2034年情绪生物标记人工智慧市场预测－全球分析（按生物标记类型、组成部分、部署模式、技术、应用、最终用户和地区划分）

Emotional Biomarker AI Market Forecasts to 2034 - Global Analysis By Biomarker Type, Component, Deployment Mode, Technology, Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球情绪生物标记 AI 市场预计将在 2026 年达到 51 亿美元，并在预测期内以 14.6% 的复合年增长率增长，到 2034 年达到 152 亿美元。

情绪生物标记人工智慧是指透过侦测和分析生理及行为讯号（例如脸部表情、语音模式、心率变异性、皮肤电导率和神经活动）来识别和分析情绪状态的人工智慧系统。这些平台处理多模态资料流，即时或透过储存记录推断情绪反应，从而应用于心理健康护理、消费者体验研究、人机互动和职场健康等领域。透过将微妙的生物和行为征兆转化为可操作的情绪智能，情绪生物标记人工智慧为临床医生、研究人员和企业开闢了理解人类的新维度。

对心理健康和保健技术的需求日益增长

全球对心理健康作为公共卫生优先事项的认识不断提高，加上对技术驱动的健康监测工具的需求日益增长，正推动着临床、消费和企业市场对情绪生物标誌物人工智慧平台的投资。医疗保健机构正在寻求客观、持续测量情绪状态的方法，以补充传统的临床评估，并改善心理健康诊断和治疗监测。同时，消费科技公司将情绪智商视为人机互动领域的下一个前沿领域。

情绪监测引发的伦理问题

引入能够持续分析和解读个体生理及行为讯号所反映的情绪状态的系统，引发了关于知情同意、情绪隐私以及情绪资料潜在操纵等方面的严重伦理问题。科技能够在个体完全不知情的情况下推断其内在情绪并据此采取行动，这种理念挑战了根深蒂固的个人自主权观念。批评者认为，商业化的情绪人工智慧系统可能会产生不准确的推理，如果用于关键决策，就会带来风险。

数位健康监测领域的应用不断扩展

数位健康监测平台、远端医疗服务和远端患者监护计画的快速发展，为情绪生物标记人工智慧（AI）技术的整合创造了极其宝贵的机会。心理健康临床医生越来越需要连续、客观的生物标记数据，以补充患者的主观自我报告，并实现更及时的治疗调整。将情绪生物标记AI技术整合到远端监测平台中，可以为临床医生提供纵向情绪轨迹数据，揭示两次治疗之间的病情恶化和好转情况，从而支持更快速、更个人化的照护。

缺乏情感人工智慧的监管标准

目前，大多数司法管辖区在情绪人工智慧领域缺乏全面的法规结构，导致在可接受的应用场景、所需的准确性标准、资料处理义务以及错误情绪推断的责任认定等方面存在诸多不确定性。欧洲及其他地区的资料保护机构正在积极考虑采取监管措施。缺乏检验的标准化生物标记通讯协定引发了人们对科学可靠性的担忧，并可能限制其临床应用；而无法证明其係统具有可重复准确性的供应商则面临声誉风险。

新冠疫情的影响：

新冠疫情对情绪生物标记人工智慧市场产生了重大影响，加速了其在医疗保健和健康领域的应用。封锁措施和日益严峻的心理健康挑战催生了对人工智慧驱动的情绪监测工具的迫切需求。各机构寻求扩充性的解决方案，以远端评估压力、焦虑和情绪健康状况，从而推动了生物标记和预测分析领域的创新。儘管供应链中断最初延缓了硬体集成，但人们对情绪健康的日益关注使人工智慧生物标誌物成为后疫情时代医疗保健战略的关键要素，并最终产生了积极的长期影响。

在预测期内，脸部表情分析细分市场预计将成为规模最大的细分市场。

脸部表情分析领域在情绪生物标记人工智慧市场中占据最大份额。电脑视觉技术能够从视讯串流中侦测细微的脸部和情绪线索，是目前最成熟、商业性化应用最广泛的情绪人工智慧技术之一。其应用范围涵盖市场调查、心理健康筛检、客户体验分析以及教育领域的参与度监测等。基于摄影机的系统的普及、广泛的商业性需求以及与数位通讯平台日益增强的融合，都巩固了该领域的市场主导地位。

预计在预测期内，软体产业将录得最高的复合年增长率。

预计在情绪生物标记人工智慧市场中，软体板块将实现最高的复合年增长率。能够处理和解读多模态情绪资料的AI分析引擎是情绪AI平台中最有价值的组成部分。随着透过云端交付的情绪智慧服务扩展到医疗保健、客户体验和企业健康管理市场，软体订阅收入正在加速成长。情绪AI API与现有业务和临床应用的日益融合，进一步推动了软体需求的成长，其成长速度超过了硬体和服务。

市占率最大的地区：

在整个预测期内，北美预计将保持最大的市场份额，这得益于其先进的医疗保健基础设施、对人工智慧研究的大力投入以及数位健康技术的广泛应用。该地区受益于人们对心理健康问题的高度关注、政府的支持性倡议以及科技公司与医疗保健提供者之间的合作。此外，领先的人工智慧公司和Start-Ups的存在正在加速情绪生物标记解决方案的创新，确保北美继续保持市场成长中心的地位。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率，这主要得益于技术的快速普及、医疗保健支出的增长以及人们对情绪健康的日益关注。中国、印度和日本等国家正在大力投资人工智慧驱动的医疗保健解决方案，并得到了不断扩展的数位生态系统和政府措施的支持。都市区压力水平的上升以及情绪生物标记人工智慧技术在远端医疗平台中的应用，进一步推动了市场需求，使亚太地区成为该市场成长最快的地区。

免费客製化服务：

所有购买此报告的客户均可享受以下免费自订选项之一：

  • 企业概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域划分
    • 应客户要求，我们提供主要国家和地区的市场估算和预测，以及复合年增长率（註：需进行可行性检查）。
  • 竞争性标竿分析
    • 根据产品系列、地理覆盖范围和策略联盟对主要企业进行基准分析。

目录

第一章执行摘要

  • 市场概览及主要亮点
  • 驱动因素、挑战与机会
  • 竞争格局概述
  • 战略洞察与建议

第二章：研究框架

  • 研究目标和范围
  • 相关人员分析
  • 研究假设和限制
  • 调查方法

第三章 市场动态与趋势分析

  • 市场定义与结构
  • 主要市场驱动因素
  • 市场限制与挑战
  • 投资成长机会和重点领域
  • 产业威胁与风险评估
  • 技术与创新展望
  • 新兴市场/高成长市场
  • 监管和政策环境
  • 新冠疫情的影响及復苏前景

第四章：竞争环境与策略评估

  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争公司之间的竞争
  • 主要企业市占率分析
  • 产品基准评效和效能比较

第五章：全球情绪生物标记人工智慧市场：依生物标记类型划分

  • 脸部表情分析
  • 语音语调分析
  • 生理讯号
    • 心率变异性
    • 皮肤电导率
  • 眼动追踪
  • 神经活动模式
  • 多模态生物标记物

第六章 全球情绪生物标记人工智慧市场：按组件划分

  • 软体
  • 硬体
  • 服务

第七章：全球情绪生物标记人工智慧市场：依部署模式划分

  • 现场
  • 基于云端的

第八章：全球情绪生物标记人工智慧市场：按技术划分

  • 机器学习
  • 电脑视觉
  • 自然语言处理
  • 穿戴式装置集成

第九章 全球情绪生物标记人工智慧市场：按应用领域划分

  • 心理健康监测
  • 客户经验分析
  • 市场研究
  • 医疗诊断
  • 汽车安全系统

第十章 全球情绪生物标记人工智慧市场：按最终用户划分

  • 医疗服务提供方
  • 公司
  • 研究机构
  • 汽车製造商
  • 学术机构

第十一章 全球情绪生物标记人工智慧市场：按地区划分

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 比利时
    • 瑞典
    • 瑞士
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 马来西亚
    • 新加坡
    • 越南
    • 其他亚太国家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
    • 智利
    • 秘鲁
    • 其他南美国家
  • 世界其他地区（RoW）
    • 中东
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 以色列
      • 其他中东国家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲国家

第十二章 策略市场资讯

  • 工业价值网络和供应链评估
  • 空白区域和机会地图
  • 产品演进与市场生命週期分析
  • 通路、经销商和打入市场策略的评估

第十三章 产业趋势与策略倡议

  • 併购
  • 伙伴关係、联盟和合资企业
  • 新产品发布和认证
  • 扩大生产能力和投资
  • 其他策略倡议

第十四章：公司简介

  • IBM Corporation
  • Microsoft Corporation
  • Google LLC
  • Amazon Web Services, Inc.
  • Apple Inc.
  • Samsung Electronics Co., Ltd.
  • Philips NV
  • Medtronic plc
  • Siemens Healthineers AG
  • Honeywell International Inc.
  • Oracle Corporation
  • Affectiva（Smart Eye AB）
  • Realeyes OU
  • Beyond Verbal
  • Thales Group
  • Lockheed Martin Corporation
  • Northrop Grumman Corporation
  • C3.ai, Inc.
Product Code: SMRC34319

According to Stratistics MRC, the Global Emotional Biomarker AI Market is accounted for $5.1 billion in 2026 and is expected to reach $15.2 billion by 2034 growing at a CAGR of 14.6% during the forecast period. Emotional biomarker AI refers to artificial intelligence systems that detect and analyze emotional states through physiological and behavioral signals including facial expressions, voice patterns, heart rate variability, skin conductance, and neural activity. These platforms process multimodal data streams to infer emotional responses in real time or through stored recordings, enabling applications in mental health care, consumer experience research, human-computer interaction, and workplace wellness. By translating subtle biological and behavioral cues into actionable emotional intelligence, emotional biomarker AI unlocks new dimensions of human understanding for clinicians, researchers, and businesses.

Market Dynamics:

Driver:

Growing mental health and wellness technology demand

Increasing global awareness of mental health as a public health priority, combined with growing demand for technology-enabled wellness monitoring tools, is driving investment in emotional biomarker AI platforms across clinical, consumer, and enterprise markets. Healthcare providers seek objective continuous measures of emotional state to supplement traditional clinical assessments and improve mental health diagnosis and treatment monitoring. Consumer technology companies see emotional intelligence as a next frontier in human-computer interaction.

Restraint:

Ethical concerns over emotional surveillance

Deployment of systems that continuously analyze and interpret an individual's emotional states from physiological and behavioral signals raises profound ethical concerns about informed consent, emotional privacy, and potential for manipulation of emotional data. The idea that technology can infer and act upon an individual's inner emotional life without their full understanding challenges deeply held notions of personal autonomy. Critics argue commercial emotion AI systems may produce inaccurate inferences used to make consequential decisions, creating risks.

Opportunity:

Expanding applications in digital health monitoring

The rapid expansion of digital health monitoring platforms, telehealth services, and remote patient monitoring programs is creating high-value integration opportunities for emotional biomarker AI capabilities. Mental health clinicians increasingly seek continuous, objective biomarker data that supplements subjective patient self-report and enables more timely therapeutic adjustments. Emotional biomarker AI embedded in remote monitoring platforms can provide clinicians with longitudinal emotional trend data that reveals deterioration or improvement between sessions, supporting more responsive and personalized care.

Threat:

Lack of regulatory standards for emotion AI

The emotional AI field currently operates without a comprehensive regulatory framework in most jurisdictions, creating significant uncertainty about permissible use cases, required accuracy standards, data handling obligations, and liability for erroneous emotional inferences. Regulatory intervention is actively being considered by data protection authorities in Europe and elsewhere. Absence of validated standardized biomarker protocols raises scientific credibility concerns that may limit clinical adoption and create reputational risks for vendors whose systems fail to demonstrate reproducible accuracy.

Covid-19 Impact:

The Covid-19 pandemic significantly influenced the Emotional Biomarker AI Market, accelerating adoption across healthcare and wellness sectors. Lockdowns and rising mental health challenges created urgent demand for AI-driven emotional monitoring tools. Organizations sought scalable solutions to assess stress, anxiety, and emotional well-being remotely, fueling innovation in biomarkers and predictive analytics. While supply chain disruptions initially slowed hardware integration, the long-term effect was positive, as awareness of emotional health surged, positioning AI biomarkers as essential in post-pandemic healthcare strategies.

The facial expression analysis segment is expected to be the largest during the forecast period

The facial expression analysis segment holds the largest share in the emotional biomarker AI market. Computer vision technology capable of detecting micro-expressions and emotional cues from video feeds is among the most mature and commercially deployed forms of emotional AI. Its applications span market research, mental health screening, customer experience analytics, and educational engagement monitoring. The accessibility of camera-based systems, broad commercial interest, and growing integration with digital communication platforms sustain this segment's dominant market position.

The software segment is expected to have the highest CAGR during the forecast period

The software segment is expected to record the highest CAGR in the emotional biomarker AI market. AI-powered analytics engines that process and interpret multimodal emotional data form the highest-value component of emotional AI platforms. As cloud-delivered emotional intelligence services expand across healthcare, customer experience, and enterprise wellness markets, software subscription revenues are accelerating. The growing integration of emotional AI APIs into existing business and clinical applications further drives software demand at a rate surpassing hardware and services.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to its advanced healthcare infrastructure, strong investment in AI research, and widespread adoption of digital health technologies. The region benefits from high awareness of mental health issues, supportive government initiatives, and collaborations between technology firms and medical institutions. Additionally, the presence of leading AI companies and startups accelerates innovation in emotional biomarker solutions, ensuring North America remains the dominant hub for market growth.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapid technological adoption, growing healthcare expenditure, and increasing awareness of emotional well-being. Countries such as China, India, and Japan are investing heavily in AI-driven healthcare solutions, supported by expanding digital ecosystems and government initiatives. Rising stress levels among urban populations and the integration of emotional biomarker AI in telemedicine platforms further drive demand, making Asia Pacific the fastest-growing region in this market.

Key players in the market

Some of the key players in Emotional Biomarker AI Market include IBM Corporation, Microsoft Corporation, Google LLC, Amazon Web Services, Inc., Apple Inc., Samsung Electronics Co., Ltd., Philips N.V., Medtronic plc, Siemens Healthineers AG, Honeywell International Inc., Oracle Corporation, Affectiva (Smart Eye AB), Realeyes OU, Beyond Verbal, Thales Group, Lockheed Martin Corporation, Northrop Grumman Corporation, and C3.ai, Inc.

Key Developments:

In February 2026, Google emphasized AI-enabled emotional biomarker technologies, projecting efficiency gains in healthcare diagnostics and consumer applications. At global summits, the company showcased demand response automation for wellness platforms, highlighting sustainability, personalization, and resilience in addressing rising emotional health challenges.

In February 2026, Apple reinforced its leadership in emotional biomarker AI, unveiling adaptive monitoring solutions integrated into wearable devices. The company demonstrated demand-responsive automation for homes and healthcare, highlighting sustainability, efficiency, and resilience in supporting personalized well-being across connected ecosystems.

In January 2026, Microsoft introduced AI-driven emotional biomarker solutions, highlighting adaptive analytics for mental health and productivity. The initiative focused on demand-responsive systems, enabling sustainable monitoring and resilience while supporting flexible deployment across homes, clinics, and industrial ecosystems globally.

Biomarker Types Covered:

  • Facial Expression Analysis
  • Voice Tone Analytics
  • Physiological Signals
  • Eye Tracking
  • Neural Activity Patterns
  • Multimodal Biomarkers

Components Covered:

  • Software
  • Hardware
  • Services

Deployment Modes Covered:

  • On-Premise
  • Cloud-Based

Technologies Covered:

  • Machine Learning
  • Computer Vision
  • Natural Language Processing
  • Wearable Integration

Applications Covered:

  • Mental Health Monitoring
  • Customer Experience Analytics
  • Market Research
  • Healthcare Diagnostics
  • Automotive Safety Systems

End Users Covered:

  • Healthcare Providers
  • Enterprises
  • Research Institutes
  • Automotive Companies
  • Academic Institutions

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Emotional Biomarker AI Market, By Biomarker Type

  • 5.1 Facial Expression Analysis
  • 5.2 Voice Tone Analytics
  • 5.3 Physiological Signals
    • 5.3.1 Heart Rate Variability
    • 5.3.2 Skin Conductance
  • 5.4 Eye Tracking
  • 5.5 Neural Activity Patterns
  • 5.6 Multimodal Biomarkers

6 Global Emotional Biomarker AI Market, By Component

  • 6.1 Software
  • 6.2 Hardware
  • 6.3 Services

7 Global Emotional Biomarker AI Market, By Deployment Mode

  • 7.1 On-Premise
  • 7.2 Cloud-Based

8 Global Emotional Biomarker AI Market, By Technology

  • 8.1 Machine Learning
  • 8.2 Computer Vision
  • 8.3 Natural Language Processing
  • 8.4 Wearable Integration

9 Global Emotional Biomarker AI Market, By Application

  • 9.1 Mental Health Monitoring
  • 9.2 Customer Experience Analytics
  • 9.3 Market Research
  • 9.4 Healthcare Diagnostics
  • 9.5 Automotive Safety Systems

10 Global Emotional Biomarker AI Market, By End User

  • 10.1 Healthcare Providers
  • 10.2 Enterprises
  • 10.3 Research Institutes
  • 10.4 Automotive Companies
  • 10.5 Academic Institutions

11 Global Emotional Biomarker AI Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 IBM Corporation
  • 14.2 Microsoft Corporation
  • 14.3 Google LLC
  • 14.4 Amazon Web Services, Inc.
  • 14.5 Apple Inc.
  • 14.6 Samsung Electronics Co., Ltd.
  • 14.7 Philips N.V.
  • 14.8 Medtronic plc
  • 14.9 Siemens Healthineers AG
  • 14.10 Honeywell International Inc.
  • 14.11 Oracle Corporation
  • 14.12 Affectiva (Smart Eye AB)
  • 14.13 Realeyes OU
  • 14.14 Beyond Verbal
  • 14.15 Thales Group
  • 14.16 Lockheed Martin Corporation
  • 14.17 Northrop Grumman Corporation
  • 14.18 C3.ai, Inc.

List of Tables

  • Table 1 Global Emotional Biomarker AI Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Emotional Biomarker AI Market Outlook, By Biomarker Type (2023-2034) ($MN)
  • Table 3 Global Emotional Biomarker AI Market Outlook, By Facial Expression Analysis (2023-2034) ($MN)
  • Table 4 Global Emotional Biomarker AI Market Outlook, By Voice Tone Analytics (2023-2034) ($MN)
  • Table 5 Global Emotional Biomarker AI Market Outlook, By Physiological Signals (2023-2034) ($MN)
  • Table 6 Global Emotional Biomarker AI Market Outlook, By Heart Rate Variability (2023-2034) ($MN)
  • Table 7 Global Emotional Biomarker AI Market Outlook, By Skin Conductance (2023-2034) ($MN)
  • Table 8 Global Emotional Biomarker AI Market Outlook, By Eye Tracking (2023-2034) ($MN)
  • Table 9 Global Emotional Biomarker AI Market Outlook, By Neural Activity Patterns (2023-2034) ($MN)
  • Table 10 Global Emotional Biomarker AI Market Outlook, By Multimodal Biomarkers (2023-2034) ($MN)
  • Table 11 Global Emotional Biomarker AI Market Outlook, By Component (2023-2034) ($MN)
  • Table 12 Global Emotional Biomarker AI Market Outlook, By Software (2023-2034) ($MN)
  • Table 13 Global Emotional Biomarker AI Market Outlook, By Hardware (2023-2034) ($MN)
  • Table 14 Global Emotional Biomarker AI Market Outlook, By Services (2023-2034) ($MN)
  • Table 15 Global Emotional Biomarker AI Market Outlook, By Deployment Mode (2023-2034) ($MN)
  • Table 16 Global Emotional Biomarker AI Market Outlook, By On-Premise (2023-2034) ($MN)
  • Table 17 Global Emotional Biomarker AI Market Outlook, By Cloud-Based (2023-2034) ($MN)
  • Table 18 Global Emotional Biomarker AI Market Outlook, By Technology (2023-2034) ($MN)
  • Table 19 Global Emotional Biomarker AI Market Outlook, By Machine Learning (2023-2034) ($MN)
  • Table 20 Global Emotional Biomarker AI Market Outlook, By Computer Vision (2023-2034) ($MN)
  • Table 21 Global Emotional Biomarker AI Market Outlook, By Natural Language Processing (2023-2034) ($MN)
  • Table 22 Global Emotional Biomarker AI Market Outlook, By Wearable Integration (2023-2034) ($MN)
  • Table 23 Global Emotional Biomarker AI Market Outlook, By Application (2023-2034) ($MN)
  • Table 24 Global Emotional Biomarker AI Market Outlook, By Mental Health Monitoring (2023-2034) ($MN)
  • Table 25 Global Emotional Biomarker AI Market Outlook, By Customer Experience Analytics (2023-2034) ($MN)
  • Table 26 Global Emotional Biomarker AI Market Outlook, By Market Research (2023-2034) ($MN)
  • Table 27 Global Emotional Biomarker AI Market Outlook, By Healthcare Diagnostics (2023-2034) ($MN)
  • Table 28 Global Emotional Biomarker AI Market Outlook, By Automotive Safety Systems (2023-2034) ($MN)
  • Table 29 Global Emotional Biomarker AI Market Outlook, By End User (2023-2034) ($MN)
  • Table 30 Global Emotional Biomarker AI Market Outlook, By Healthcare Providers (2023-2034) ($MN)
  • Table 31 Global Emotional Biomarker AI Market Outlook, By Enterprises (2023-2034) ($MN)
  • Table 32 Global Emotional Biomarker AI Market Outlook, By Research Institutes (2023-2034) ($MN)
  • Table 33 Global Emotional Biomarker AI Market Outlook, By Automotive Companies (2023-2034) ($MN)
  • Table 34 Global Emotional Biomarker AI Market Outlook, By Academic Institutions (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.